Nonpeptide αvβ3 antagonists.: 1.: Transformation of a potent, integrin-selective αIIbβ3 antagonist into a potent αvβ3 antagonist

被引:83
作者
Duggan, ME [1 ]
Duong, LT
Fisher, JE
Hamill, TG
Hoffman, WF
Huff, JR
Ihle, NC
Leu, CT
Nagy, RM
Perkins, JJ
Rodan, SB
Wesolowski, G
Whitman, DB
Zartman, AE
Rodan, GA
Hartman, GD
机构
[1] Merck Res Labs, Dept Med Chem, West Point, PA 19486 USA
[2] Merck Res Labs, Dept Bone Biol & Osteoporosis Res, West Point, PA 19486 USA
[3] Merck Res Labs, Dept Pharmacol, West Point, PA 19486 USA
关键词
D O I
10.1021/jm000133v
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Modification of the potent fibrinogen receptor (alpha(IIb)beta(3)) antagonist 1 generated compounds with high affinity for the vitronectin receptor alpha(v)beta(3). Sequential modification of the basic N-terminus of 1 led to the identification of the 5,6,7,8-tetrahydro[1,8]naphthyridine moiety (THN) as a lipophilic, moderately basic N-terminus that provides molecules with excellent potency and selectivity for the integrin receptor alpha(v)beta(3). The THN-containing analogue 5 is a potent inhibitor of bone resorption in vitro and in vivo. In addition, the identification of a novel, nonpeptide radioligand with high affinity to alpha(v)beta(3) is also reported.
引用
收藏
页码:3736 / 3745
页数:10
相关论文
共 35 条
[1]   Non-peptide glycoprotein IIb/IIIa inhibitors .17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists [J].
Askew, BC ;
Bednar, RA ;
Bednar, B ;
Claremon, DA ;
Cook, JJ ;
McIntyre, CJ ;
Hunt, CA ;
Gould, RJ ;
Lynch, RJ ;
Lynch, JJ ;
Gaul, SL ;
Stranieri, MT ;
Sitko, GR ;
Holahan, MA ;
Glass, JD ;
Hamill, T ;
Gorham, LM ;
Prueksaritanont, T ;
Baldwin, JJ ;
Hartman, GD .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (12) :1779-1788
[2]   Disubstituted indazoles as potent antagonists of the integrin αvβ3 [J].
Batt, DG ;
Petraitis, JJ ;
Houghton, GC ;
Modi, DP ;
Cain, GA ;
Corjay, MH ;
Mousa, SA ;
Bouchard, PJ ;
Forsythe, MS ;
Harlow, PP ;
Barbera, FA ;
Spitz, SM ;
Wexler, RR ;
Jadhav, PK .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (01) :41-58
[3]  
CHAMBERS TJ, 1984, J CELL SCI, V66, P383
[4]  
CHAMBERS TJ, 1986, BONE MINER, V1, P127
[5]  
CLOVER J, 1992, J CELL SCI, V103, P267
[6]  
Colman RW, 1987, HEMOSTASIS THROMBOSI
[7]  
Cook Nigel S., 1994, Drugs of the Future, V19, P135
[8]   Antibody to beta(3) integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat [J].
Crippes, BA ;
Engleman, VW ;
Settle, SL ;
Delarco, J ;
Ornberg, RL ;
Helfrich, MH ;
Horton, MA ;
Nickols, GA .
ENDOCRINOLOGY, 1996, 137 (03) :918-924
[9]  
DUGGAN ME, 1976, 211 NAT ACS M NEW OR
[10]   Treatment of postmenopausal osteoporosis [J].
Eastell, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (11) :736-746